Mandate

Vinge advises Yubico in the merger with ACQ Bure  

ACQ Bure AB, a Swedish acquisition company (Special Purpose Acquisition Company) listed on Nasdaq Stockholm and Yubico AB have signed a merger agreement and adopted a joint merger plan to combine ACQ and Yubico.

Yubico is a leading provider of multi-factor cybersecurity solutions. Yubico’s hardware-based security key, YubiKey, is a leading solution for protection against phishing attacks, and works across hundreds of consumer and enterprise applications and services. Yubico’s technology enables secure authentication, encryption, and code signing and is used by many of the world’s largest organizations and millions of users in more than 160 countries

The transaction values Yubico’s shares at 800 MUSD and is expected to be completed during the third quarter 2023, subject to, among other things, approval by the general meeting in ACQ and Yubico, respectively.

Vinge’s team consisted of Jonas Johansson, Maria Dahlin Kolvik and Gustav Wahlberg (M&A) as well as Linnea Sellström (Public M&A).

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025